Condition: Ovarian Cancer · Cognitive Impairment · Sponsor: University of California, Irvine
This is a phase I, dose-escalation and phase II dose-expansion clinical trial determining the maximum tolerated dose (MTD) and safety and tolerability of adding N-Acetyl-Cysteine (NAC) to ovarian cancer patients who are receiving a platinum-based therapy (PBT). This study will investigate whether NAC will mitigate chemotherapy-related cognitive impairment (CRCI).
This description comes directly from the study's public registry record.
Chao Family Comprehensive Cancer Center University of California, Irvine · 1-877-827-7883 · ucstudy@uci.edu
University of California Irvine Medical
Always discuss trial participation with your own doctor first.
| Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange, California, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04520139